Laurie G Jacobs1,2, Elli Gourna Paleoudis3, Dineen Lesky-Di Bari4, Themba Nyirenda3, Tamara Friedman3, Anjali Gupta1,2, Lily Rasouli2, Marygrace Zetkulic1,2, Bindu Balani1,5, Chinwe Ogedegbe6,7, Harinder Bawa1,2,8,9, Lauren Berrol10, Nabiha Qureshi2, Judy L Aschner8,9. 1. Department of Internal Medicine, Hackensack Meridian School of Medicine, Nutley, New Jersey, United States of America. 2. Department of Internal Medicine, Hackensack University Medical Center, Hackensack, New Jersey, United States of America. 3. Office of Research Administration, Hackensack Meridian Health, Edison, New Jersey, United States of America. 4. Department of Research, Joseph M. Sanzari Children's Hospital at Hackensack University Medical Center, Hackensack, New Jersey, United States of America. 5. Division of Infectious Disease, Department of Internal Medicine, Hackensack University Medical Center, Hackensack, New Jersey, United States of America. 6. Department of Emergency Medicine, Hackensack Meridian School of Medicine, Nutley, New Jersey, United States of America. 7. Hackensack University Medical Center, Hackensack, New Jersey, United States of America. 8. Department of Pediatrics, Hackensack Meridian School of Medicine, Nutley, New Jersey, United States of America. 9. Joseph M. Sanzari Children's Hospital at Hackensack University Medical Center, Hackensack, New Jersey, United States of America. 10. Department of Anesthesiology, Hackensack University Medical Center, Hackensack, New Jersey, United States of America.
Abstract
BACKGROUND: Characterizing the prevalence and persistence of symptoms associated with COVID-19 infection following hospitalization and their impact is essential to planning post-acute community-based clinical services. This study seeks to identify persistent COVID-19 symptoms in patients 35 days post-hospitalization and their impact on quality of life, health, physical, mental, and psychosocial function. METHODS AND FINDINGS: This prospective cohort study used the PROMIS® Instruments to identify symptoms and quality of life parameters in consecutively enrolled patients between March 22 and April 16, 2020, in New Jersey. The 183 patients (median age 57 years; 61.5% male, 54.1% white) reported persistent symptoms at 35 days, including fatigue (55.0%), dyspnea (45.3%), muscular pain (51%), associated with a lower odds rating general health (41.5%, OR 0.093 [95% CI: 0.026, 0.329], p = 0.0002), quality of life (39.8%; OR 0.116 [95% CI: 0.038, 0.364], p = 0.0002), physical health (38.7%, OR 0.055 [95% CI: 0.016, 0.193], p <0.0001), mental health (43.7%, OR 0.093 [95% CI: 0.021, 0.418], p = 0.0019) and social active role (38.7%, OR 0.095 [95% CI: 0.031, 0.291], p<0.0001), as very good/excellent, particularly adults aged 65 to 75 years (OR 8·666 [95% CI: 2·216, 33·884], p = 0·0019). CONCLUSIONS: COVID-19 symptoms commonly persist to 35 days, impacting quality of life, health, physical and mental function. Early post-acute evaluation of symptoms and their impact on function is necessary to plan community-based services.
BACKGROUND: Characterizing the prevalence and persistence of symptoms associated with COVID-19infection following hospitalization and their impact is essential to planning post-acute community-based clinical services. This study seeks to identify persistent COVID-19 symptoms in patients 35 days post-hospitalization and their impact on quality of life, health, physical, mental, and psychosocial function. METHODS AND FINDINGS: This prospective cohort study used the PROMIS® Instruments to identify symptoms and quality of life parameters in consecutively enrolled patients between March 22 and April 16, 2020, in New Jersey. The 183 patients (median age 57 years; 61.5% male, 54.1% white) reported persistent symptoms at 35 days, including fatigue (55.0%), dyspnea (45.3%), muscular pain (51%), associated with a lower odds rating general health (41.5%, OR 0.093 [95% CI: 0.026, 0.329], p = 0.0002), quality of life (39.8%; OR 0.116 [95% CI: 0.038, 0.364], p = 0.0002), physical health (38.7%, OR 0.055 [95% CI: 0.016, 0.193], p <0.0001), mental health (43.7%, OR 0.093 [95% CI: 0.021, 0.418], p = 0.0019) and social active role (38.7%, OR 0.095 [95% CI: 0.031, 0.291], p<0.0001), as very good/excellent, particularly adults aged 65 to 75 years (OR 8·666 [95% CI: 2·216, 33·884], p = 0·0019). CONCLUSIONS:COVID-19 symptoms commonly persist to 35 days, impacting quality of life, health, physical and mental function. Early post-acute evaluation of symptoms and their impact on function is necessary to plan community-based services.
Authors: Bruno Biagianti; Asia Di Liberto; Aiello Nicolò Edoardo; Ilaria Lisi; Letizia Nobilia; Giulia Delor de Ferrabonc; Elisa R Zanier; Nino Stocchetti; Paolo Brambilla Journal: Front Aging Neurosci Date: 2022-07-01 Impact factor: 5.702
Authors: Alicja Mińko; Agnieszka Turoń-Skrzypińska; Aleksandra Rył; Natalia Tomska; Zuzanna Bereda; Iwona Rotter Journal: Int J Environ Res Public Health Date: 2022-06-30 Impact factor: 4.614
Authors: Ani Nalbandian; Kartik Sehgal; Aakriti Gupta; Mahesh V Madhavan; Claire McGroder; Jacob S Stevens; Joshua R Cook; Anna S Nordvig; Daniel Shalev; Tejasav S Sehrawat; Neha Ahluwalia; Behnood Bikdeli; Donald Dietz; Caroline Der-Nigoghossian; Nadia Liyanage-Don; Gregg F Rosner; Elana J Bernstein; Sumit Mohan; Akinpelumi A Beckley; David S Seres; Toni K Choueiri; Nir Uriel; John C Ausiello; Domenico Accili; Daniel E Freedberg; Matthew Baldwin; Allan Schwartz; Daniel Brodie; Christine Kim Garcia; Mitchell S V Elkind; Jean M Connors; John P Bilezikian; Donald W Landry; Elaine Y Wan Journal: Nat Med Date: 2021-03-22 Impact factor: 53.440
Authors: Maddalena Peghin; Alvisa Palese; Margherita Venturini; Maria De Martino; Valentina Gerussi; Elena Graziano; Giulia Bontempo; Francesco Marrella; Alberto Tommasini; Martina Fabris; Francesco Curcio; Miriam Isola; Carlo Tascini Journal: Clin Microbiol Infect Date: 2021-06-07 Impact factor: 13.310